MetaCap

Kiora Pharmaceuticals (KPRX) vs Medicus Pharma (MDCX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicus Pharma (MDCX) has outperformed Kiora Pharmaceuticals (KPRX) over the past year, losing 46.7% versus a loss of 61.5%. Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KPRX-61.49%MDCX-46.71%
+76%-14%-104%
Nov 21, 20251 yearNov 20, 2026
KPRX-78.11%MDCX-49.33%
+242%+65%-112%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KPRX versus MDCX key metrics
MetricKPRXMDCX
Share price$0.7202$1.14
Market cap$3.19M$3.16M
1-day change-12.28%-2.16%
YTD return-63.44%-25.82%
1-year return-61.49%-46.71%
5-year return-99.87%—
EPS (TTM)$-2.72$-76.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.84M$-47.28M
52-week high$2.91$114.00
52-week low$0.72$1.06
Distance from 52-week high-75.25%-99.00%
Analyst consensusnonenone
Avg. price target upside+1566.20%+296.48%
Average volume35.23K116.55K
Shares outstanding4.42M2.79M
Employees1316
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MDCX has outperformed KPRX by 14.8 percentage points over the past year.

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Medicus Pharma

MDCX stock →

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

KPRX vs MDCX FAQ

Which is bigger, Kiora Pharmaceuticals or Medicus Pharma?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.16M for Medicus Pharma (MDCX).

Which stock has performed better over the past year, KPRX or MDCX?

MDCX returned -46.71% over the past 12 months, compared with -61.49% for KPRX (price return, excluding dividends). Past performance does not predict future results.

Are Kiora Pharmaceuticals and Medicus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons